Abstract 4459
Background
IO has become one of the major pillars of anti-cancer therapy. A range of immune-related adverse events (IRAE) are recognized within various organs. Acute vascular events (AVE) are generally not considered IRAE. Considering the role of inflammation in acute ischemic cardiovascular events, we assumed such events can be triggered by IO. We aimed to evaluate the frequency and nature of AVEs occurring shortly after the initiation of IO.
Methods
Computerized search of Sheba medical center (SMC) electronic medical records was done for patients (pts) that received IO (any of: pembrolizumab, nivolumab, atezolizumab, ipilimumab). Out of those, we searched for cases with a diagnosis of AVE within 1 month after initiation of IO. Search was for the diagnoses: cerebrovascular accident (CVA), transient ischemic attack (TIA), myocardial infarct (MI), non-ST-elevation MI, ST-elevation MI, embolic event, pulmonary emboli (PE) and deep vein thrombosis (DVT). We excluded cases with AVE within a year prior to the initiation of therapy, concomitant chemotherapy, and cases of a single-site DVT.
Results
Between 1st January 2015 and 14th March 2018, 1396 pts received IO in SMC. 14 pts were identified in the computerized search. Excluded: 4 with a single site DVT, 1 with a prior cardiovascular event within a year prior to initiation of IO, 1 with concomitant chemotherapy, 3 excluded due to AVE not definitely diagnosed, leaving 5 pts not excluded. 8 additional pts were identified by reports of physicians aware of this project, of these 2 were also identified by the computerized search, thus a total of 11 pts fit our study criteria. Events were: multiple CVA (3), PE (2), sudden cardiac death (2), bilateral DVT (1), CVA (1), TIA (1), MI (1). In one pt marantic endocarditis was suspected. 7 pts had diabetes, 7 pts had hypertension, 2 pts had a body mass index > 30, 3 were smoking within < 10 years ago, none had a family history of cardiovascular disease. 9 of the pts were treated in SMC, constituting a frequency of 0.6%.
Conclusions
AVEs occur at a low frequency shortly after initiation of IO. Initiation of IO may be the trigerring event of those events. Further retrospective studies and analyses of clinical trials data are required to evaluate whether this is a random association or a true IRAE.
Clinical trial identification
Legal entity responsible for the study
Sheba Medical Center, Tel Hashomer, Israel.
Funding
Sheba Medical Center.
Editorial Acknowledgement
Disclosure
J. Bar: Consultant fees: Roche, Boehringer Ingelheim, Novartis, BMS, MSD, Pfizer, AstraZeneca, VBL, Takeda; Grant support: Boehringer Ingelheim, Novartis, AstraZeneca, MSD, Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract